Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Dexcom (DXCM)

Dexcom (DXCM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,894,204
  • Shares Outstanding, K 95,742
  • Annual Sales, $ 1,476 M
  • Annual Income, $ 101,100 K
  • 60-Month Beta 0.79
  • Price/Sales 25.16
  • Price/Cash Flow 162.24
  • Price/Book 27.43
Trade DXCM with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.64
  • Number of Estimates 12
  • High Estimate 0.82
  • Low Estimate 0.48
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -1.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
373.41 +10.07%
on 10/06/20
420.00 -2.14%
on 10/01/20
+24.93 (+6.46%)
since 09/23/20
3-Month
373.41 +10.07%
on 10/06/20
456.23 -9.91%
on 08/07/20
-9.01 (-2.15%)
since 07/23/20
52-Week
145.23 +183.00%
on 10/25/19
456.23 -9.91%
on 08/07/20
+264.54 (+180.62%)
since 10/23/19

Most Recent Stories

More News
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

DexCom (DXCM) closed at $387.84 in the latest trading session, marking a -1.17% move from the prior day.

DXCM : 411.00 (+3.84%)
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

SYK : 221.90 (-1.22%)
MASI : 244.77 (+2.13%)
DXCM : 411.00 (+3.84%)
PACB : 13.90 (+0.91%)
Will DexCom (DXCM) Beat Estimates Again in Its Next Earnings Report?

DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

DXCM : 411.00 (+3.84%)
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

DexCom (DXCM) closed the most recent trading day at $394.01, moving -1.73% from the previous trading session.

DXCM : 411.00 (+3.84%)
SmarTrend Watching for Potential Pullback in Shares of Dexcom After 2.01% Gain

Dexcom (NASDAQ:DXCM) traded in a range yesterday that spanned from a low of $394.47 to a high of $402.90. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $401.55...

DXCM : 411.00 (+3.84%)
Dexcom Appoints Kyle Malady to Board of Directors

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Kyle Malady to its Board of Directors, effective immediately.

DXCM : 411.00 (+3.84%)
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, DexCom (DXCM) closed at $387.50, marking a -1.6% move from the previous day.

DXCM : 411.00 (+3.84%)
Global Outlook for the Continuous Glucose Monitoring Systems Market to 2027, Featuring Profiles of Key Players Abbott Laboratories, DexCom Inc. and Medtronic Plc

, /PRNewswire/ -- The report has been added to offering.

ABT : 107.79 (-1.54%)
DXCM : 411.00 (+3.84%)
Lilly and Dexcom team up on new program to help improve diabetes management

and , /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DexCom, Inc. (NASDAQ: DXCM) announced today a joint program for U.S. healthcare providers (HCPs) about Lilly's new rapid-acting mealtime insulin...

LLY : 142.38 (+0.52%)
DXCM : 411.00 (+3.84%)
DexCom (DXCM) Gains But Lags Market: What You Should Know

In the latest trading session, DexCom (DXCM) closed at $413.84, marking a +0.39% move from the previous day.

DXCM : 411.00 (+3.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes.

See More

Key Turning Points

2nd Resistance Point 420.64
1st Resistance Point 415.82
Last Price 411.00
1st Support Level 401.57
2nd Support Level 392.15

See More

52-Week High 456.23
Last Price 411.00
Fibonacci 61.8% 337.43
Fibonacci 50% 300.73
Fibonacci 38.2% 264.03
52-Week Low 145.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar